Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Common Stock : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Cyclacel Pharmaceuticals Common Stock?

Cyclacel Pharmaceuticals's quarterly common stock declined from Jun. 2023 ($4.50 Mil) to Sep. 2023 ($0.01 Mil) and declined from Sep. 2023 ($0.01 Mil) to Dec. 2023 ($0.00 Mil).

Cyclacel Pharmaceuticals's annual common stock increased from Dec. 2021 ($0.01 Mil) to Dec. 2022 ($4.50 Mil) but then declined from Dec. 2022 ($4.50 Mil) to Dec. 2023 ($0.00 Mil).

Cyclacel Pharmaceuticals Common Stock Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Common Stock Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.01

4.50

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															4.50	4.50	4.50	0.01	-

Cyclacel Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.